Linked Life Data

8201608

Source:http://linkedlifedata.com/resource/pubmed/id/8201608

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1994-7-7
pubmed:abstractText
The current policy of drug regulatory authorities demanding that pharmaceutical companies justify their reasons for preferring drugs containing a mixture of enantiomers over one stereoisomer increases the importance of quantitative structure-activity relations (QSARs) for chiral drugs. The QSAR proposed by Pfeiffer for chiral drug enantiomer potencies was brought into question by the existence of sets obeying an anti-Pfeiffer rule. Using computer-aided molecular design methods and treating chirality not as an existing/nonexisting property but as a continuous one improve the QSAR proposed by Pfeiffer, yielding higher correlation coefficients and an independent ordinate. Calculated shape similarities reveal the details of the Pfeiffer behavior and the source of the anti-Pfeiffer behavior. Consequently revised models for the D2 and sigma receptor are suggested.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
27
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1727-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Molecular similarity, quantitative chirality, and QSAR for chiral drugs.
pubmed:affiliation
Physical Chemistry Laboratory, Oxford, United Kingdom.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't